Jonathan McNeill - 15 Nov 2023 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Role: Chief Business Officer
Signature: /s/ Richard Scalzo, Attorney-in-Fact
Issuer symbol: DYN
Transactions as of: 15 Nov 2023
Transactions value $: $0
Form type: 4
Filing time: 16 Nov 2023, 16:34:50 UTC
Previous filing: 20 Sep 2023
Next filing: 12 Dec 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DYN	Common Stock	Award	$0	+96,158	+159%	$0	156,763	15 Nov 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DYN	Stock Option (right to buy)	Award	$0	+37,445		$0	37,445	15 Nov 2023	Common Stock	37,445	$10.88	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Consists of shares of Common Stock issuable under 96,158 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on February 15, 2024.
F2	Includes 147,149 unvested RSUs.
F3	This option was granted on November 15, 2023. The shares underlying the option are scheduled to vest over four years in equal monthly installments through November 15, 2027.